– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) –
– Company reducing its workforce by 73% –
– Cash and investments of $183.8 million (unaudited) as of December 31, 2024 –
https://www.globenewswire.com/news-release/2025/01/09/3007285/0/en/IGM-Biosciences-Provides-Strategic-Update-on-Autoimmunity-Pipeline-Programs.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.